Control of Enzyme Activity

Enzymes don't just speed up reactions — they can be turned on, off, and fine-tuned to meet the cell's needs. This guide moves from the kinetics framework through the regulatory strategies the MCAT tests.

Priority labels: Must know = cold; Know the logic = mechanism not names; Passage-level = recognize, don't memorize; Optional = skippable.

---

Catalysis: What Enzymes Actually Do

Lowering the Activation Energy

Must know

Every reaction has an energy hill — the activation energy ($E_a$). Enzymes are catalysts that lower $E_a$ without being consumed and without changing the thermodynamics of the reaction ($\Delta G$, $K_{eq}$, and reactant/product energies are unchanged). The enzyme just makes it easier to get over the hill.

Enzymes lower $E_a$ by stabilizing the transition state — the highest-energy configuration mid-reaction. The active site is complementary to the transition state (not just the substrate), which is why transition-state analogs bind tightly and act as potent inhibitors.

Know the logic

Enzymes accomplish this through proximity/orientation effects, general acid-base catalysis, covalent catalysis, metal-ion catalysis, and electrostatic stabilization — all consequences of the active site's 3-D structure. Because activity depends on that structure, denaturation (heat, extreme pH) destroys activity even with the sequence intact.

Quick check: A researcher finds that a drug lowers the activation energy of a reaction catalyzed by an enzyme but does NOT change $\Delta G$. Is this consistent with catalysis?

Answer: Yes. Catalysts, including enzymes, lower $E_a$ but leave the overall thermodynamics unchanged. The drug may be acting as a co-catalyst or facilitating the reaction mechanism.

---

Michaelis-Menten Kinetics (Brief Recap)

Must know

Regulation only makes sense against the basic kinetic framework, so here is the minimum you need; the full treatment — $k_{cat}$, catalytic efficiency, the Lineweaver-Burk plot, and worked examples — lives in the 5E Enzymes guide.

$v = \frac{V_{max}[\text{S}]}{K_m + [\text{S}]}$

• $V_{max}$ = maximum velocity, reached when the enzyme is saturated with substrate.
• $K_m$ = Michaelis constant = the substrate concentration at which $v = \frac{1}{2}V_{max}$.
• $K_m$ is an inverse measure of affinity — low $K_m$ = high affinity (half-maximal velocity at low $[\text{S}]$); high $K_m$ = low affinity.

---

Cooperativity

Why Some Enzymes Don't Follow Michaelis-Menten

Must know

Many regulatory enzymes are oligomeric (multiple subunits), and substrate binding at one subunit changes the shape of its neighbors. This is cooperativity.

Positive Cooperativity and the Sigmoidal Curve

Must know

In positive cooperativity, the first substrate makes subsequent binding easier, giving a sigmoidal (S-shaped) curve instead of a hyperbola. At low $[\text{S}]$ the enzyme is in the low-affinity T-state; as a few molecules bind, it switches to the high-affinity R-state.

Know the logic

The Hill equation describes this, with Hill coefficient $n$ as the measure of cooperativity:

$v = \frac{V_{max}[\text{S}]^n}{K_{0.5}^n + [\text{S}]^n}$

$n > 1$ = positive cooperativity; $n = 1$ = none (Michaelis-Menten); $n < 1$ = negative. $K_{0.5}$ is $[\text{S}]$ at half-max (analogous to $K_m$). You only need the qualitative meaning of $n$, not the equation's algebra.

The Canonical Example: Hemoglobin vs. Myoglobin

Must know

This comparison appears constantly:

Property	Myoglobin	Hemoglobin
Subunits	1	4
Cooperative?	No	Yes (positive)
$\text{O}_2$ curve	Hyperbolic	Sigmoidal
Function	$\text{O}_2$ storage (muscle)	$\text{O}_2$ transport (blood)

Hemoglobin's sigmoidal curve lets it bind $\text{O}_2$ avidly in the lungs (high $\text{O}_2$) yet unload it efficiently in tissues (low $\text{O}_2$) — the steep transition maximizes the saturation difference, which a hyperbola couldn't.

Passage-level

The Bohr effect (↓ affinity with ↓ pH / ↑ $\ce{CO2}$) and 2,3-BPG (stabilizes T-state) are allosteric extensions of this.

Quick check: Phosphofructokinase-1 (PFK-1), a key glycolysis enzyme, shows sigmoidal kinetics with respect to its substrate fructose-6-phosphate. What does a Hill coefficient of ~4 tell you, and what is the role of ATP?

Answer: PFK-1 has strong positive cooperativity with respect to fructose-6-phosphate. Binding of F6P to one subunit strongly promotes binding at additional subunits, giving the enzyme an "on/off" switch-like behavior rather than a gradual response — ideal for controlling flux through a metabolic pathway. ATP plays a dual role: it is a substrate at the active site but also an allosteric inhibitor at a separate regulatory site, so high ATP (energy abundance) shifts the F6P curve to the right.

---

Inhibition (Pointer)

Small-molecule inhibitors modulate enzyme activity, and feedback inhibition (below) is a biological case of it. The four inhibition types defined by their effects on apparent $K_m$ and $V_{max}$ — competitive, uncompetitive, noncompetitive, and mixed — together with their Lineweaver-Burk signatures, are covered in full in the 5E Enzymes guide.

---

Feedback Regulation

The Logic of Feedback

Must know

Cells sense the end product of a pathway and use it to inhibit a key enzyme early in that pathway — feedback (end-product) inhibition, a form of allosteric regulation. When product is abundant, it binds the regulatory site and shuts the pathway down; when product is consumed, inhibition is relieved.

Feedback targets the first committed step (the first reaction unique to the pathway), so one control point governs the whole pathway and no resources are wasted on intermediates.

Passage-level

Mammalian PFK-1 (committed step of glycolysis) is inhibited by ATP and citrate (energy abundance) and activated by AMP/ADP (energy deficit).

Quick check: In the pyrimidine synthesis pathway, CTP (the end product) inhibits carbamoyl phosphate synthetase II, the first enzyme in the pathway. What is this called, and what is the biological rationale?

Answer: This is feedback inhibition (specifically product inhibition or end-product inhibition). When CTP is abundant, there is no need to make more pyrimidines, so the pathway shuts off automatically. This conserves ATP and precursor molecules. When CTP is consumed, inhibition is relieved and synthesis resumes.

---

Regulatory Enzymes

Beyond small-molecule inhibitors, cells use structural and covalent mechanisms to toggle enzymes between active/inactive states. The MCAT tests three categories.

Allosteric Enzymes

Must know

Allosteric enzymes have a separate regulatory site where effectors bind, causing a conformational change that modulates the active site. Activators stabilize the active R-state (shift curve left); inhibitors stabilize the inactive T-state (shift right, or lower $V_{max}$). Allosteric enzymes are usually oligomeric, often cooperative (sigmoidal), and serve as pathway rate-limiting steps.

Optional

The textbook example is ATCase in pyrimidine synthesis (CTP inhibits, ATP activates).

Quick check: ATCase catalyzes the committed step in pyrimidine biosynthesis; CTP is an allosteric inhibitor. If you add excess CTP and plot $v$ vs. $[\text{S}]$, how does the curve change?

Answer: It stays sigmoidal but shifts right — CTP stabilizes the T-state, lowering apparent affinity for aspartate, so more substrate is needed for the same velocity.

Covalently Modified Enzymes

Must know

A chemical group is reversibly added or removed, toggling activity. The key example is phosphorylation — added by kinases (from ATP), removed by phosphatases. Effect can be activation OR inhibition depending on the enzyme; there is no universal rule.

Know the logic

Reciprocal regulation: during fight-or-flight (epinephrine → ↑cAMP → ↑PKA), one signal phosphorylates several enzymes at once so that opposing pathways aren't run simultaneously — e.g., glycogen phosphorylase is activated while glycogen synthase is inactivated.

Optional

Other modifications include acetylation, methylation, and ADP-ribosylation; pyruvate dehydrogenase and acetyl-CoA carboxylase are also inactivated by phosphorylation.

Quick check: Protein kinase A (PKA) phosphorylates both glycogen phosphorylase kinase (activating it) and glycogen synthase (inactivating it). Why is this reciprocal regulation physiologically smart?

Answer: During a stress response, the cell needs glucose fast. Simultaneously activating glycogen breakdown and inhibiting glycogen synthesis through a single signaling cascade (cAMP → PKA) ensures that the cell is not wastefully making and breaking down glycogen at the same time. It's metabolic efficiency — one signal coordinates two opposing pathways.

Zymogens (Proenzymes)

Must know

A zymogen (proenzyme) is an inactive precursor activated by irreversible proteolytic cleavage — removing a peptide exposes the active site. Cells use this when an active enzyme would be dangerous at its site of synthesis: digestive proteases would digest the pancreas itself (pancreatitis). Because the cleaved peptide diffuses away, activation is irreversible — the key contrast with reversible phosphorylation.

Know the logic

Cascade amplification: enterokinase activates trypsin, which then activates chymotrypsinogen, proelastase, and more trypsinogen (autocatalysis), so one signal is massively amplified.

Passage-level

Recognize, don't memorize the whole list: pepsinogen→pepsin (autocatalytic at low pH), trypsinogen→trypsin (enterokinase), chymotrypsinogen→chymotrypsin (trypsin), prothrombin→thrombin and plasminogen→plasmin (clotting/fibrinolysis cascades).

Quick check: A pancreatitis patient has elevated serum trypsin. Explain how premature trypsinogen activation causes this, using the zymogen concept.

Answer: Normally trypsinogen is activated only in the duodenum by enterokinase. In pancreatitis it is activated prematurely inside acinar cells, where active trypsin activates other zymogens in an uncontrolled cascade, digesting the pancreas (autodigestion); the enzymes leak into blood, raising serum trypsin.

---

Common Confusions & Tricks

1. Competitive vs. noncompetitive on the Lineweaver-Burk — which axis is "fixed"?
Remember: Competitive = same y-intercept (C and y both start with something round — think "C for Ceiling = $V_{max}$ doesn't change"). Noncompetitive = same x-intercept ($K_m$ doesn't change). Write "CI = $V_{max}$ unchanged" on your scratch paper.

2. Uncompetitive is the counterintuitive one.
Most students assume that if an inhibitor lowers $K_m$, it must be an activator. Wrong — uncompetitive inhibitors lower both $K_m$ AND $V_{max}$. The decreasing $K_m$ reflects the stabilization of ES (trapping substrate in a non-productive complex), not true activation. Parallel lines on Lineweaver-Burk = uncompetitive, always.

3. $K_m$ is NOT always equal to $K_d$ (affinity).
$K_m$ is a kinetic ratio that incorporates $k_{cat}$. Only when $k_{cat} \ll k_{-1}$ does $K_m \approx K_d$. The MCAT sometimes tests this distinction.

4. Enzymes don't change equilibrium — they change rate.
A catalyst speeds up both the forward and reverse reactions equally. If an MCAT question asks whether an enzyme changes the equilibrium constant or $\Delta G°'$, the answer is always no.

5. "High $K_m$" = "low affinity" — get this direction right.
Students often flip it. High $K_m$ means you need a lot of substrate to get to half-maximal velocity — the enzyme barely "notices" the substrate at normal concentrations. Low $K_m$ = avid binding = high affinity.

6. Zymogens are irreversibly activated; phosphorylation is reversible.
If an exam scenario describes "activation by removal of a peptide segment," that's irreversible proteolytic activation. If it describes "addition of a phosphate group," that's covalent modification, which is reversible (phosphatases can remove the phosphate).

7. Noncompetitive inhibition is a special case of mixed inhibition.
Mixed inhibition is the general case where the inhibitor binds E and ES with different affinities. When affinities are equal, it becomes pure noncompetitive. On the MCAT, treat them as distinct unless told otherwise.

8. Sigmoidal curve ≠ automatically Michaelis-Menten breakdown.
A sigmoidal $v$ vs. $[\text{S}]$ curve signals cooperative binding — use the Hill equation framework, not Michaelis-Menten. But if asked about $V_{max}$ (which still exists for cooperative enzymes at saturation), you can still discuss it.

9. Competitive inhibitors increase apparent $K_m$, not true $K_m$.
The intrinsic affinity of the enzyme for substrate doesn't actually change — it's the apparent (observed) $K_m$ that increases because inhibitor is competing. This distinction matters for mechanism questions.

10. Remember the cascade purpose for zymogens.
If a passage describes an enzyme being activated by cleavage in a cascade, think: (1) What dangerous outcome does the zymogen strategy prevent? (2) What amplification does the cascade provide? These are the two key biological rationales the MCAT tests.

---

Key Equations

Equation	Variables & Usage
$v = \dfrac{V_{max}[\text{S}]}{K_m + [\text{S}]}$	Michaelis-Menten equation; $v$ = reaction velocity, $V_{max}$ = maximum velocity, $K_m$ = substrate concentration at $\frac{1}{2}V_{max}$, $[\text{S}]$ = substrate concentration
$\dfrac{1}{v} = \dfrac{K_m}{V_{max}} \cdot \dfrac{1}{[\text{S}]} + \dfrac{1}{V_{max}}$	Lineweaver-Burk (double-reciprocal); y-intercept $= 1/V_{max}$, x-intercept $= -1/K_m$, slope $= K_m/V_{max}$
$V_{max} = k_{cat} \times [E_T]$	Relates turnover number ($k_{cat}$, s$^{-1}$) and total enzyme concentration to $V_{max}$; used to find $k_{cat}$
$\text{Catalytic efficiency} = \dfrac{k_{cat}}{K_m}$	Second-order rate constant for substrate capture; higher = better enzyme; diffusion limit ~$10^8$–$10^9\ \text{M}^{-1}\text{s}^{-1}$
$v = \dfrac{V_{max}[\text{S}]^n}{K_{0.5}^n + [\text{S}]^n}$	Hill equation for cooperative binding; $n$ = Hill coefficient ($n>1$: positive cooperativity, $n=1$: Michaelis-Menten, $n<1$: negative cooperativity)
$\ce{E + S <=> ES -> E + P}$	Minimal enzyme kinetic scheme underlying Michaelis-Menten kinetics